44 results
ARS
2023 FY
CRBU
Caribou Biosciences Inc
25 Apr 24
Annual report to shareholders
4:06pm
our allogeneic cell therapies for the treatment of hematologic malignancies. Our therapies are directed at established cell surface targets for which … ”), as well as targets such as C-type lectin-like molecule-1 (“CLL-1,” also known as CD371). We use our chRDNA technologies to armor our cell therapies through
8-K
EX-99.2
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
-010 is an allogeneic CAR-T cell therapy that targets autoantibody-producing B cells 1 To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T … CAR-T cells in lupus2 CB-010 TCR KO Anti-CD19 CAR PD-1 KO Anti-CD19 CAR targets autoantibody-producing B cells Engineered for improved activity
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
4 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4:05pm
role in lupus by producing autoantibodies that cause the immune system to attack healthy tissues. CB-010 targets CD19, a protein on the surface of B
424B5
0g865fy sx
14 Jul 23
Prospectus supplement for primary offering
5:31pm
424B5
r66 ypyd69t98cnfw
13 Jul 23
Prospectus supplement for primary offering
4:56pm
8-K
EX-99.2
uyvte vdfds
13 Jul 23
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
4:23pm
ARS
atp4urj i3rk
28 Apr 23
Annual report to shareholders
12:00am
DEFA14A
6e4u63492fnune
11 Aug 22
Additional proxy soliciting materials
4:06pm
DEF 14A
hmae svx25fwqyq
11 Aug 22
Definitive proxy
4:04pm
S-3
vny3n2x
9 Aug 22
Shelf registration
12:00am
10-K
jo8cx
21 Mar 22
Annual report
4:19pm